Acepodia (ROCO:6976) Treasury Stock : NT$0.00 Mil (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Acepodia Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Acepodia's treasury stock for the quarter that ended in Jun. 2024 was NT$0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Acepodia Treasury Stock Historical Data

The historical data trend for Acepodia's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acepodia Treasury Stock Chart

Acepodia Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Treasury Stock

Acepodia Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Treasury Stock	Get a 7-Day Free Trial			-	-	-	-	-

Acepodia Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Acepodia Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acepodia Inc (ROCO:6976) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

17th floor-12, Number 99, Section 1, Xintai 5th Road, Xizhi District, New Taipei, TWN, 22175

Website

https://www.acepodia.com

Acepodia Inc is a clinical stage biotechnology company engaged to develop innovative highly effective first-in-class cell therapies by using Antibody-Cell Conjugation platform technology for cancer that are broadly accessible for patients.

Acepodia Headlines

No Headlines